Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial.
The lancet oncology.
Times cited: 102
PDGF receptor alpha is an alternative mediator of rapamycin-induced akt activation: Implications for combination targeted therapy of synovial sarcoma.
Times cited: 32